Is Retrieval of Bone Material From Multiorgan Donors Effective Enough to Cover Demand for Biostatic Bone Tissue Grafts in Poland?

Bohatyrewicz, Andrzej; Bohatyrewicz, Romuald; Dobiecki, Konrad; Kotrych, Daniel; Kamiński, Adam; Zienkiewicz, M.; Ziętek, Paweł; Dziedzic‐Goclawska, A.

doi:10.1016/j.transproceed.2005.11.075

Cited by 4 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bone autogra s are considered the gold standard in lling bone defects after curettage, however, this method has some restrictions, such as donor site morbidity, the limited availability of gra s of su cient size and shape, and additional proce-dures for harvesting [9]. On the other hand, allogra s have a high complication rate [10]. Due to the limitations of the above-mentioned methods, synthetic bone substitutes were sought.…”

Section: Introductionmentioning

confidence: 99%

The use of bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Zrodowski¹,

Ciechanowicz²,

Dembski³

et al. 2022

Chir. Narzadow Ruchu Ortop. Pol.

View full text Add to dashboard Cite

Introduction. Treatment of benign bone tumors and tumor-like lesions is undertaken by numerous Orthopedic surgeons worldwide. Several treatment modalities exist including curettage and bone grafting. CERAMENT is a novel bioresorbable bone substitute used for grafting. Aim. Assessment of preliminary result of treatment of benign bone tumors and tumors like lesions utilizing CERAMENT as a bone substitute. Analysis of therapeutic and diagnostic path and symptoms reported by patients with tumors and tumor-like lesions. Materials and methods. To the retrospective study 38 patients undergoing curettage and bone substitution with CERAMENT® BONE VOID FILLER were included (26% of them were females). We utilized patients’ history. Each patient had an X-ray in the twelfth month after surgery, which was analyzed using the modified Neer classification. The follow-up was 24 months. Results. The unicameral bone cyst was the most commonly encountered lesion (36.8%). Pain was the most common symptom reported (28.9%). Half of all cases were discovered accidentally on X-rays ordered for a different indication. Nearly a quarter of the cases (23.7%) were complicated by pathologic fracture. The distribution of scores in modified Neer score was as follow: SCORE I- 52.6% SCORE II- 15.8% SCORE III-10.6% SCORE IV-2.6%. Complications of procedure were noted in 18.4% of patients. 10.5% of patients had serious discharge from the operated site, 7.9% of patients had surgical wound infection. One case of recurrence was noted. Conclusions. Bone substitute – CERAMENT is suitable for use in the treatment of benign bone tumors and tumors like lesions. It is easy in application and is well tolerated by the patients. The problem is the relatively high rate of complications, mainly serous leakage from the wound.

show abstract

Section: Introductionmentioning

confidence: 99%

The use of bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Zrodowski¹,

Ciechanowicz²,

Dembski³

et al. 2022

Chir. Narzadow Ruchu Ortop. Pol.

View full text Add to dashboard Cite

show abstract

“…Complication rates of 20% have been reported. Similarly, allografts have a high complication rate [ 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

et al. 2018

View full text Add to dashboard Cite

AbstractBackground: CERAMENT™|BONE VOID FILLER is an injectable and moldable ceramic bone substitute material intended for bone voids. The material consists of hydroxyapatite and calcium sulfate hemihydrate. The aim of this study is to present the first long-term results following open curettage of benign bone tumors and tumor-like lesions and void filling with this novel injectable and synthetic bone graft. Methods: Thirty three patients were enrolled into the study between June 2013 and October 2014 .Totally, we treated 24 women and 9 men with a median age of 47 years (range: 22-74). All patients suffered from primary musculoskeletal system disorders (enchondroma 63,6%, giant cell tumor 18%, aneurysmal bone cyst 9%, fibrous dysplasia 9%, Gaucher disease 3%). We performed curettage of pathological lesions, then the bone substitute was administered by means of needle to the void. Results: The average follow-up was 13 months (range: 2-13 months, median 10 months). No metastasis or recurrence had been detected. We received significant clinical improvement relating to VAS, MSTS, and oncological results. Conclusions: The results of our study report that CERAMENT can be successfully used as a bone substitute in patients with various bone diseases, as well as benign bone tumors. CERAMENT can provide an effective and long-term solution for reconstructive procedures following curettage of bone tumors and tumor like lesions.

show abstract

Treatment of Spinal Aneurysmal Bone Cyst with Percutaneous Injection of Hydroxyapatite Osteoconductive Cement

Gragnano,

Opancina,

Muto

et al. 2023

Cardiovasc Intervent Radiol

View full text Add to dashboard Cite

Is Retrieval of Bone Material From Multiorgan Donors Effective Enough to Cover Demand for Biostatic Bone Tissue Grafts in Poland?

Cited by 4 publications

References 9 publications

The use of bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

The use of bone substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Preliminary results of Highly Injectable Bi-Phasic Bone Substitute (CERAMENT) in the treatment of benign bone tumors and tumor-like lesions

Treatment of Spinal Aneurysmal Bone Cyst with Percutaneous Injection of Hydroxyapatite Osteoconductive Cement

Contact Info

Product

Resources

About